Bunkerhill AVC vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Bunkerhill AVC

by BunkerHill Health

EchoNext

by Pathway Labs

AI Verdict

Both Bunkerhill AVC and EchoNext are FDA-cleared AI tools in cardiology that offer clinical decision support. Bunkerhill AVC focuses on the automated detection and quantification of various calcifications from CT scans, while EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure and valve disease. The choice between them depends on whether the primary need is CT-based calcification analysis or ECG-based structural heart disease detection.

Choose Bunkerhill AVC if…

Choose Bunkerhill AVC if your healthcare system regularly performs chest CTs for various indications and you want to opportunistically screen for aortic valve calcification (AVC) and other cardiovascular risks. This tool is ideal for integrating with existing EHRs and clinical archives to automate the detection and quantification of AVC, coronary artery calcification (CAC), and mitral annular calcification (MAC) from both non-contrast and contrast-enhanced CT scans, enabling early detection and proactive management of conditions like aortic stenosis.

View Bunkerhill AVC →

Choose EchoNext if…

Choose EchoNext if you are looking for a non-invasive, AI-powered screening tool to detect hidden structural heart disease (SHD) from standard 12-lead ECGs. This tool is best suited for broad access screening in various clinical settings, from major hospitals to community practices, to identify patients at high risk for conditions such as heart failure, valve disease, and pulmonary hypertension who may require further echocardiography.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Bunkerhill AVC	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Integrates with full Electronic Health Records (EHRs) and clinical archives within health systems.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext is deployed through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, suggesting a wide reach and integration into existing clinical workflows. This broad platform availability likely contributes to easier adoption and a more streamlined user experience for a large number of clinicians. Bunkerhill AVC integrates with EHRs and clinical archives, but its generative AI platform, Carebricks, also allows health systems to build and deploy customizable AI agents, which might imply a more complex initial setup or customization process.

Clinical Value

EchoNext

EchoNext has demonstrated superior diagnostic accuracy, identifying 77% of structural heart problems compared to 64% for cardiologists without AI assistance and 69% with AI assistance in a head-to-head comparison. It also identifies a broader range of conditions from a standard ECG, including heart failure, valve disease, and pulmonary hypertension. While Bunkerhill AVC is FDA-cleared for early detection and quantification of aortic valve calcification and other calcifications from CTs, EchoNext's ability to detect multiple hidden structural heart diseases from a routine ECG offers significant potential for earlier, non-invasive screening and intervention.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, including details on implementation fees and annual discounts, making its cost structure clear to potential buyers. Bunkerhill AVC's pricing is listed as 'contact for pricing,' which lacks transparency and makes it difficult to assess its value proposition without direct engagement.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness. Bunkerhill AVC integrates with full EHRs and clinical archives and has secured a national billing code from CMS for its AI-enabled cardiovascular analysis, which is crucial for widespread adoption and reimbursement within health systems. EchoNext is available through the OpenEvidence platform, used by a large number of physicians, and has also received significant seed funding to support expansion across health systems and further clinical validation.

Innovation

Bunkerhill AVC

Bunkerhill Health's Carebricks platform utilizes generative AI for clinical reasoning and action, allowing for customizable AI agents and natural language processing for patient record interaction. This goes beyond detection and quantification to enable more dynamic and adaptable AI applications in healthcare workflows. While EchoNext is innovative in its ability to detect multiple structural heart diseases from ECGs, Bunkerhill's generative AI approach offers a broader scope for future development and customization.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details regarding the level of support or documentation available for either Bunkerhill AVC or EchoNext. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Bunkerhill AVC	EchoNext
Tool Name	Bunkerhill AVC	EchoNext
Company	BunkerHill Health	Pathway Labs
Description	FDA-cleared algorithm for early detection and quantification of aortic valve calcification from chest CTs, part of a generative AI platform for clinical reasoning and action.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	Generative AI for clinical reasoning and action, Automated detection and quantification of aortic valve calcification (Bunkerhill AVC), Automated detection and quantification of coronary artery calcification (iCAC, Contrast CAC), Automated detection and quantification of mitral annular calcification (Bunkerhill MAC), Opportunistic bone density assessment (Bunkerhill BMD), Integration with Electronic Health Records (EHRs) and clinical archives, Customizable AI agents for diverse workflows, Natural language processing for patient record interaction (Carebricks Chat)	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support
Specialties	Cardiology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill AVC and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing physician workflows and EHR systems?

Bunkerhill AVC integrates with full EHRs and clinical archives to automate workflows, identify patients, create referrals or orders, and send notifications, operating with real-time read-and-write capabilities within the EHR. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a significant number of U.S. physicians, aiming to put screening output in front of physicians within their existing tools.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

Bunkerhill AVC demonstrated a low mean difference in Agatston-equivalent scores and met precision (0.826) and recall (0.855) criteria in its pivotal study for aortic valve calcification detection. EchoNext achieved an AUROC of 85.2% in internal tests and 78-80% in external validation for detecting structural heart disease, outperforming cardiologists who achieved 64% accuracy (77% for AI alone).

Given their specialized focus, how well do these tools fit into different cardiology subspecialties or broader clinical contexts?

Bunkerhill AVC is specifically designed for opportunistic detection and quantification of aortic valve calcification from chest CTs, which is relevant for cardiology and radiology, and can also be used for coronary artery calcification and mitral annular calcification. EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, making it broadly applicable across cardiology, family medicine, hospital medicine, and internal medicine for early screening.

What is the expected learning curve for physicians and clinical staff to effectively use these tools?

Bunkerhill's Carebricks platform, which includes AVC, is designed to enable AI-powered workflows that analyze patient records and clinical guidelines, aiming to minimize added workload for clinicians by supporting chart review, determining follow-up eligibility, and guiding next steps. EchoNext is integrated into the OpenEvidence platform, suggesting it's designed to be accessible within tools physicians already use, potentially reducing the learning curve for adoption.

What kind of customer support and resources are available to ensure successful implementation and ongoing use?

Bunkerhill Health emphasizes partnering with health systems to operationalize AI with speed and flexibility, offering their Carebricks platform to design, test, and deploy AI agents. Pathway Labs, the company behind EchoNext, focuses on providing quality, accuracy, and exceptional customer service, and offers a contact option for questions, inquiries, or business proposals.

What audit-trail features are available to track the AI's recommendations and subsequent clinical actions?

Bunkerhill's Carebricks platform enables workflows that can complete downstream actions within clinical systems, such as creating referrals or orders and messaging patients and providers, implying a system that can track these automated steps. While specific audit-trail features are not detailed for EchoNext, its integration with a clinical decision support platform like OpenEvidence suggests a framework for tracking AI-driven insights within a clinical context.

How do these tools support multi-site rollout and ensure consistent performance across diverse clinical environments?

Bunkerhill AVC's performance was validated in a retrospective study using data from 33 sites across three geographical regions in the United States, indicating its generalizability. EchoNext has demonstrated consistent performance across diverse patient demographics, clinical contexts, and numerous hospitals, with validation on external cohorts from multiple health systems, suggesting robust multi-site applicability.